Contrast Enhanced MRI of the Prostate
The purpose of this study is to assess whether the new quantitative MRI method can discriminate between malignant and benign prostate tissue (diagnostic) and differentiate aggressive from indolent prostate cancer (disease monitoring and differentiation).
Patients with abnormal findings on Digital Rectal Examination (DRE) or elevated Prostate-Specific Antigen (PSA) test.
Patients with known prostate cancer on active surveillance and scheduled for biopsy repeat or choose radical prostatectomy as disease management.
For prostate cancer diagnosis: Any patient with abnormal findings on Digital Rectal Examination or with elevated PSA.
For prostate cancer aggressiveness monitoring: prostate cancer patient scheduled for clinical biopsy or radical prostatectomy.
18 - 75
Healthy Volunteers Needed
Duration of Participation
The MRI scan time is about 60 minutes.
Mr. William Woodward (503) 418-1526.
Dr. Xin Li (503) 418-1533.